Clinical trial
Bortezomib in Treating Patients With Recurrent Glioma
NCT00006773 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00006773 |
|---|---|
| Title | Bortezomib in Treating Patients With Recurrent Glioma |
| Official title | Phase I Evaluation of the Safety of PS 341 in the Treatment of Recurrent Gliomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor |
| Intervention type | Drug |
| Interventions | bortezomib |
| Enrollment | 42 |
| Start date | May 1, 2001 |
| Primary completion | Jun 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: